Search Results

assessed features associated with rapid relapse TNBC (rrTNBC) and found that higher stage at diagnosis, younger age at diagnosis, lower income, and insurance type were significantly associated with rrTNBC. The goal of the present study was to identify

Insights discuss the updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with previously untreated and relapsed/refractory disease. First

with relapsed sALCL Review the options for desensitization in patients with relapsed or refractory sALCL and hypersensitivity to brentuximab vedotin Case Report A 32-year-old woman with a medical history of super obesity (body mass index

consensus exists regarding frontline therapy for MCL, although standards are emerging. The management of relapsed MCL is an area of intense study. This review discusses the current landscape and emerging therapies for MCL in both the front-line and relapsed

CAR T, HCPs estimated that 21.6% of patients were refractory to CAR T and 28.0% relapsed post-CAR T. While 44.0% of HCPs were indifferent to treatment formats, they perceived a large patient preference for subcutaneous (58.7%) versus intravenous (12

% reporting a preference for HDT/ASCR consolidation after CHOP+/-R induction. Figure 1 Preferred induction therapy. In the relapsed setting ( Figure 2 ), bendamustine+/-R was the most commonly preferred salvage therapy for oncologists in the

study, the definition was stringent (MR5.0), but further research confirmed that lowering the threshold to a molecular response of 4.5 or 4.0 did not significantly affect rates of molecular relapse ( Figure 1 ). 2 Figure 1. Impact of different molecular

-mutant AML (either newly diagnosed or relapsed/refractory) is now standard of care. The phase III RATIFY study performed in younger patients (aged 18–60 years) with newly diagnosed FLT3 -mutant AML found that individuals receiving midostaurin in

their specific needs. When putting AYA outcomes into this context, it is important to consider both patient-level and healthcare-level factors. Several domains in these levels that influence both clinical outcomes (such as relapse and survival) and

relapsed or refractory disease, various salvage therapies are available, but immunotherapies have produced a paradigm shift in response rates. At the NCCN 2020 Virtual Congress: Hematologic Malignancies, Patrick A. Brown, MD, Professor of Oncology, The